Arca
Skip to content
Tools
Tools

ITGB6: Integrin beta-6

Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ITGB6, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Antibody-drug conjugate 1

Approved0

    Phase 31

    • Sigvotatug vedotin

    Phase 21

    • Sigvotatug

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Sigvotatug vedotinPhase 3PfizerAntibody-drug conjugateBinding agentIntegrin beta-6 binding agent4
      SigvotatugPhase 2PfizerAntibodyInhibitorIntegrin beta-6 inhibitor4

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
      Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersSigvotatug, Sigvotatug vedotinPhase 1 / Phase 2RecruitingPfizerNov 12, 2025
      This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.Sigvotatug, Sigvotatug vedotinPhase 3RecruitingPfizerJan 3, 2025
      A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerSigvotatug, Sigvotatug vedotinPhase 3Active, not recruitingSeagen, a wholly owned subsidiary of PfizerAug 25, 2023
      A Study of Sigvotatug Vedotin in Advanced Solid TumorsSigvotatug, Sigvotatug vedotinPhase 1RecruitingSeagen, a wholly owned subsidiary of PfizerMay 15, 2020

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Amelogenesis imperfecta0.61
      • Amelogenesis imperfecta type 10.61
      • Smoking initiation0.40
      • Alopecia - intellectual disability syndrome0.39
      • Hypocalcified amelogenesis imperfecta0.37
      • Non-small cell lung carcinoma0.34
      • Adolescent idiopathic scoliosis0.33
      • Type 2 diabetes mellitus0.21

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4876, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P18564, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.